LIFE OS learned 7 things this week.
A new treatment-response phenotype emerged
28 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 30; clinical recognition has typically come at day 77.
9 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 18% and 71% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 6.8× more likely to reach high discontinuation risk than the program average (57 patients).
Unexpected strong responders
42 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.
Delayed loss of response without toxicity
45 patients lose response from the second month with no toxicity signal. Step count and adherence drift precede it by about two weeks.
22 predicted discontinuations in the next 30 days
Most share GI intolerance as the leading driver. Predicted persistence gain from the best historic action is +17%.
42 patients likely to develop worse nausea within 14 days
GI symptom score is rising week over week. Hydration and dose-timing protocols were the most accepted actions in this situation.